Home >

Welcome to ASCO Connection Discussion

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
Jan 11, 2017 2:00 PM
Read more to answer the following questions: 1) Which tests are the most appropriate in identifying a BRAF codon 600 mutation for potential FDA-targeted treatment? 2) What is the significance of the CDKN2A mutation? 3) If systemic therapy is selected, would you be more inclined to offer targeted...
International
ASCO International Affairs
Dec 21, 2016 11:45 AM
ASCO recently partnered with local organizers to hold an International Palliative Care Workshop in China and a Cancer Control in Primary Care course in Brazil.
The IPCW was held in Luoyang in October in partnership with the 1st Affiliated Hospital of Henan University of Science and Technology. More...
Molecular Oncology Tumor Board
ASCO University
Dec 07, 2016 8:16 AM
Read more to answer the following questions:
Is further tissue needed to confirm radiologically presumed metastatic disease or for repeat HER2 testing? What systemic therapy option would you recommend for confirmed HER2 negative metastatic gastric cancer?
Molecular Oncology Tumor Board
ASCO University
Nov 09, 2016 11:09 AM
Read more to answer the following questions:

 Recognize the clinical characteristics and outcomes for patients with FLT3 mutations?
Describe the role of FLT3 inhibitors for the initial treatment of AML?
Understand the role of gene mutations, including CLT3,  in the pathologic classification of...
International
ASCO International Affairs
Oct 25, 2016 3:08 PM
The American Society of Clinical Oncology, in collaboration with the Ghana Medical Association, presented a two-day Cancer Control in Primary Care course focused on breast and cervical cancers in Accra, Ghana in September 2016. In addition to lectures, the course included breakout sessions with...

Pages

Tweets from ASCO

Tweets from Oncology Community